Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, OrigiMed Collaborate to Develop Cancer Assays

NEW YORK (GenomeWeb) – Shanghai, China-based cancer precision medicine company OrigiMed said today it will collaborate with Illumina to develop oncology assays.

The firms will develop the new assays on Illumina's next-generation sequencing instruments for cancer molecular diagnostics. OrigiMed will also develop a bioinformatics solution for medical institutions.

OrigiMed is currently equipped with one of Illumina's NovaSeq 6000, four NextSeq 500s and one MiniSeq.